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M.E.L. van der Burg,’ G. Bolis,” P. J.M. Bakker,’ D. Curran,4 T. Sahmoud” and 
J. B . Vermorken5 
‘Department of Med:ical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University 
Hospital, PO Box 5201, 3008 AE, Rotterdam, The Netherlands; ?stituto Nazionale per lo Studio e la Cura 
dei Tumori, Milano, Italy; ‘Academic Medical Center, Amsterdam; ‘EORTC Data Center, Brussels, 
Belgium; and *Free University Hospital, Amsterdam, The Netherlands 
In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly 
bolus injection of 4’-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior 
radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One 
patient had a complete response and 2 patients had a partial response, one was an unconfirmed par- 
tial response, giving a response rate of 14%. Six patients had stable disease. The median pro- 
gression-free survival and overall survival was 2.8 months and 6.1 months, respectively. In 
conclusion, 4’-epidoxorubicin used at this dosage and schedule has minimal activity in metastatic 
adenocarcinoma of the cervix. 0 1997 Elsevier Science Ltd. 
EurJ Cancer, Vol. 33, No. 9, pp. 1513-1515, 1997 
INTRODUCTION 
CHEMOTHERAPY IN disseminated cancer of the uterine cervix 
is still a palliative treatment [ 11. Although with combination 
chemotherapy, higher response rates have been reported, 
the response duration and survival are generally short. 
Doxorubicin as well as 4’-epidoxorubicin as a three- 
weekly schedule at doses of 50 mg/m” and higher, has 
shown antitumour activity in carcinoma of the uterine cervix 
[4-91. Response rates of 20-48% have been observed, but 
at the cost of considerable toxicity, especially in those 
patients who had received prior extensive pelvic radiother- 
apy [4-61. Weekly low-dose 4’-epidoxorubicin at a dose of 
20 mg total (approximately 12.5 mg/m2) has been suggested 
to be as effective as three-weekly high dose 4’-epidoxorubi- 
tin in patients with breast cancer but is significantly less 
toxic [lo, Ill. 
We investigated whethe:r an effective palliation with mini- 
mal toxicity could be achieved with weekly low-dose 4’-epi- 
doxorubicin in patients with metastatic carcinoma of the 
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uterine cervix, squamous cell or adenocarcinoma. We pre- 
viously reported a 4% partial response rate in squamous cell 
carcinoma of the cervix [ 121. The present report is on ade- 
nocarcinoma of the cervix. 
PATIENTS AND METHODS 
Eligibility criteria included histologically confirmed ade- 
nocarcinoma of the primary tumour of the cervix; measur- 
able or evaluable disease outside previously irradiated areas 
with documented progression; life expectancy of at least 2 
months; WHO performance score 2; age ~80 years; no 
prior radiotherapy or chemotherapy for at least 4 weeks 
before entry (mitomycin C, nitrosoureas and extensive 
radiotherapy for at least 6 weeks) and recovery from toxic 
effects of prior treatment; no prior therapy with antracy- 
clines; white blood cell count (WBC) > 3 x 109/1, platelet 
count > 100 x lo9 fl; normal bilirubin; no active cardiac dis- 
ease; no clinical signs of brain involvement or leptomenin- 
geal disease; informed consent prior to therapy. 
Treatment consisted of a weekly dose of 12.5 mg/m2 4’- 
epidoxorubicin by intravenous bolus injection. If WBC was 
3 x 109/1 and/or platelets ~75 x lo911 treatment was delayed 
by 1 week. If after 1 week postponement the WBC was 
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Table 1. Patient and tumour characteristics at entry RESULTS 
n WI 
Twenty-three patients were entered into this phase II 
study, 22 of whom were eligible; 1 patient was excluded 
because all measurable lesions had been previously irra- 
diated. The patient and tumour characteristics for all eli- 
gible patients are summarized in Table 1. None of the 
patients received prior chemotherapy. The median interval 
between diagnosis and start of chemotherapy was 18 
months (range O-81 months), the median treatment-free 
interval was 13 months (range O-69 months). The median 
number of administered cycles was six (range l-46). Eight 
patients received less than six cycles because of early pro- 
gression (6 patients), early death (1 patient), and another 
patient was lost to follow-up after 2 cycles. 
Patients 
Age (years) 
Median (range) 
WHO performance status 
0 
1 
2 
FIG0 stage 
I 
II 
III 
IV 
Extent of the disease at entry 
Primary only 
Loco-regional recurrent 
Metastatic only 
Primary not excised and 
metastatic 
Loco-regional recurrent and 
metastatic 
Prior treatment 
Surgery 
None 
Curative 
Palliative 
Prior radiotherapy 
No 
Yes 
No response 
Response 
Adjuvant 
Site of radiotherapy 
Primary unresected tumour 
Postoperative on site of resection 
Postoperative on lung and bone 
metastases 
Unknown 
Sites of disease 
Lung 
Lymph node 
Liver 
Bone 
Locoregional 
Skin 
22 (100) 
59 (35-70) 
6 (27) 
9 (41) 
7 (32) 
10 
3 
7 
2 
2 
3 
11 
3 
3 
10 
10 
2 
5 
17 
5 
7 
5 
7 
4 
1 
5 
10 
7 
1 
3 
12 
1 
(45) 
(14) 
(32) 
(9) 
(9) 
(14) 
(50) 
(14) 
(14) 
(45) 
(45) 
(9) 
(23) 
(77) 
(23) 
(32) 
(23) 
(32) 
(18) 
(5) 
(23) 
(45) 
(32) 
(5) 
(14) 
(55) 
(5) 
between 2.0 and 2.9 x lo9 /l and/or the platelets between 75 
and 99 x 109/1, the dose was reduced by 50%, but if WBC 
was still C2.0 x 109/1 and/or platelets <75 x 109/1, treatment 
was delayed another week for a maximum of 3 weeks. 
Response was evaluated by computer tomography (CT) 
scan, gynaecological and complete physical examination 
after 6 cycles. Responses were defined according to the 
WHO response criteria [I 31. The sample size calculation 
was based on the two-stage Gehan’s design, aiming to 
include 14 patients and then adding other patients for each 
response seen in the first stage [ 141. This guarantees that 
the probability of an active treatment (real response rate 
220%) exhibiting no response in the first 14 patients (that 
is, false-negative result) is 0.05 and allows an estimate of 
the therapeutic effectiveness with a standard error of 10% 
[14]. Survival curves and time to progression curves were 
estimated using the Kaplan-Meier technique [ 141. 
In general, treatment was well tolerated. Nausea and 
vomiting WHO grade 1 was observed in 8 patients (36%), 
grade 2 in 1 patient (5%) and grade 3 in 2 patients (9%). 
One patient (5%) had mucositis grade 1, 4 patients (18%) 
had alopecia grade 1 and 2 patients (9%) had grade 2. 
Myelotoxicity was mild. The median WBC nadir was 
6.0 x lo911 (range 2.1-14.5). The median platelet count 
nadir was 240 x 109/1 (range 60-575). Treatment delay was 
reported in 8 patients, in whom 2 were drug related: severe 
vomiting in one and thrombocytopenia in the other. 
(a) 
n 0 
22 16 All pts - 
6 9 12 15 18 
Months 
(b) 
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Months 
Figure 1. Time to progression (a) and overall survival (b). 
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Four patients were not evaluable for response: 1 patient 
had an early death not treatment or tumour related; 1 
patient refused treatment after the first cycle; 1 patient was 
lost to follow-up after two cycles; and no CT scan was per- 
formed for the fourth patient after three cycles as the clini- 
cal condition worsened. 
One complete and two partial responses, one not con- 
firmed, was observed in the 22 eligible patients, giving a re- 
sponse rate of 14% (95% exact confidence interval: 3- 
35%). Complete response was observed in a patient with a 
lymph node metastasis outside the irradiated area; the treat- 
ment-free interval was only 1 month; she received a total of 
10 cycles. The response lasted for 16 months, and she was 
still alive after a follow-up of 34 months. The patient with 
the partial response developed lung metastases 18 months 
after radiotherapy to the primary tumour, she received 26 
cycles. The response lasted more than 4 months. One other 
patient had a partial respcsnse of the primary tumour after 6 
cycles, but the patient refused further treatment; she was 
irradiated to the indicator lesion before response confir- 
mation. Six patients (27%) had a stable disease and 9 
patients (41%) had progression. The median progression- 
free survival of the 22 eligible patients was 2.8 months and 
the median duration of survival was 6.1 months (Figure 1). 
DISCUSSION 
The haematological and non-haematological toxicity from 
weekly low-dose 4’-epidoxorubicin was mild, especially mye- 
lotoxicity. Only in 1 patient did thrombocytopenia exceed 
grade one toxicity. The response rate (14%) was somewhat 
higher than those observed in epithelial cervical cancer (4%) 
[ 121. However, the median progression-free survival and 
overall survival were only 2.8 months and 6.1 months, re- 
spectively. 
The response rate of 4’-epidoxorubicin in this trial is dis- 
appointing in view of its activity in other tumours. This may 
be partically explained by the relatively low dose chosen for 
this trial. Despite this low dose, some activity was observed 
(14% based on all eligible patients and 17% if based on the 
18 patients who were evaluable for response). Therefore, 
further investigation of the drug with higher doses, es- 
pecially in view of the mild toxicity, may be recommended. 
Another possibility could be using 4’-epidoxorubicin in 
combination with other drugs. Cisplatin might be a reason- 
able choice as the combination of cisplatin and doxorubicin 
proved active in adenocarcinoma of the endometrium [ 161. 
In conclusion, weekly low dose 4’-epidoxorubicin as single 
agent at a dose of 12.5 mg/m’ has low activity and should 
not be used in metastatic adenocarcinoma of the cervix. 
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